Use of low molecular weight heparin in cats: 57 Cases (1999-2003)

Journal of the American Veterinary Medical Association

Volumn 225, Issue 8, 2004, Pages 1237-1241

  Smith, Caren E ^a   Rozanski, Elizabeth A ^a   Freeman, Lisa M ^a   Brown, Donald J ^a   Goodman, Jennifer S ^a,b   Rush, John E ^a  

^a TUFTS UNIVERSITY   (United States)

^b Angell Memorial Animal Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; STREPTOKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA THROMBOSIS; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CARDIOMYOPATHY; CAT; DRUG TOLERABILITY; FOLLOW UP; NONHUMAN; RETROSPECTIVE STUDY; TELEPHONE; THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CAT DISEASES; CATS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; INJECTIONS, SUBCUTANEOUS; MALE; RETROSPECTIVE STUDIES; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANIMALIA; FELIS CATUS;

EID: 5444274685     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.2004.225.1237     Document Type: Article

References (31)

1. Rush JE, Freeman LM, Fenollosa NK, et al. Population and survival characteristics of cats with hypertropic cardiomyopathy: 260 cases (1990-1999). J Am Vet Med Assoc 2002;220:202-207.
2. Tilley LP, Liu SK, Gilbertson SR, et al. Primary myocardial disease in the cat. A model for human cardiomyopathy. Am J Pathol 1977;86:493-522.
3. Laste NJ, Harpster NK. A retrospective study of 100 cases of feline distal aortic thromboembolism: 1977-1993. J Am Anim Hosp Assoc 1995;31:492-500.
4. Smith SA, Tobias AH, Jacob KA, et al. Arterial thromboembolism in cats: acute crisis in 127 cases (1992-2001) and long-term management with low-dose aspirin in 24 cases. J Vet Intern Med 2003;17:73-83.
5. Pion PD, Kittleson MD. Therapy for feline aortic thromboembolism. In: Kirk RW, ed. Current veterinary therapy X. Philadelphia: WB Saunders, 1989;295-302.
6. Moore KE, Morris N, Dhupa N, et al. Retrospective study of streptokinase administration in 46 cats with arterial thromboembolism. J Vet Emerg Crit Care 2000;10:245-257.
7. Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003;145:614-621.
8. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-809.
9. Lopez-Beret P, Orgaz A, Fontcuberta J, et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 2001;33:77-90.
10. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one year results of the ESSENCE Study. Efficacy and safety of subcutaneous enoxaparin in non-Q wave coronary events. J Am Coli Cardiol 2000;36:693-698.
11. Harenberg J, Weuster B, Dempfle CE, et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemost 1993;19(suppl 1):116-121.
12. Kontny F, Dale J, Abildgaard U, et al. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol 1997;30:962-969.
13. Young E, Cosmi B, Weitz J, et al. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (enoxaparin) to plasma proteins. Thromb Haemost 1993;70:625-630.
14. Young E, Wells P, Holloway S, et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparins. Thromb Haemost 1994;71:300-304.
15. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698.
16. Bratt G, Tornebohm E, Widlund L, et al. Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986;42:613-620.
17. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445.
18. Schwarzwald CC, Feige K, Wunderli-Allenspach H, et al. Comparison of pharmacokinetic variables for two low-molecular-weight heparins after subcutaneous administration of a single dose to horses. Am J Vet Res 2002;63:868-873.
19. Monreal L, Villatoro AJ, Monreal M, et al. Comparison of the effects of low-molecular-weight and unfractionated heparin in horses. Am J Vet Res 1995;56:1281-1285.
20. Mischke R, Grebe S. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following administration of a low molecular weight heparin. Res Vet Sci 2000;69:241-247.
21. Mischke R, Grebe S, Jacobs C, et al. Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs. Am J Vet Res 2001;62:595-598.
22. Harenberg J, Huhle G, Piazolo L, et al. Long-term anticoagulation of outpatients with adverse effects to oral anticoagulants using low-molecular-weight heparin. Semin Thromb Hemost 1997;23:167-172.
23. Hirsh J. Heparin. N Engl J Med 1991;324:1565-1572.
24. Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000;20:771-775.
25. Sanderink GJ, Guimart CG, Ozoux ML, et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225-231.
26. Andrew M, Ofosu F, Brooker L, et al. The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig. Thromb Res 1989;56:529-539.
27. Grebe S, Jacobs C, Kietzmann M, et al. Pharmakokinetik des niedermolekularen heparins Fragmin D beim Hund. Berl Munch Tierarztl Wochenschr 2000;113:103-107.
28. Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191-202.
29. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
30. Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996;76:195-199.
31. Atkins CE, Gallo AM, Kurzman ID, et al. Risk factors, clinical signs and survival in cats with a clinical diagnosis of idiopathic hypertrophic cardiomyopathy: 74 cases (1985-1989). J Am Vet Med Assoc 1992;201:613-618.